emerg
novel
sar
coronaviru
trigger
ongo
global
pandem
sever
pneumonialik
diseas
design
coronaviru
diseas
date
million
confirm
case
death
report
worldwid
current
medic
countermeasur
avail
prevent
treat
diseas
develop
vaccin
could
requir
least
month
typic
timelin
hit
find
drug
registr
antivir
year
reposit
known
drug
significantli
acceler
develop
deploy
therapi
identifi
therapeut
repurpos
antivir
profil
librari
known
drug
encompass
approxim
clinicalstag
fdaapprov
small
molecul
report
identif
known
drug
inhibit
viral
replic
six
character
cellular
doseact
relationship
show
effect
concentr
like
commensur
therapeut
dose
patient
includ
pikfyv
kinas
inhibitor
apilimod
cystein
proteas
inhibitor
z
lvg
ono
antagonist
sinc
mani
molecul
advanc
clinic
known
pharmacolog
human
safeti
profil
compound
acceler
preclin
clinic
evalu
treatment
authorfund
right
reserv
reus
allow
without
permiss
decemb
novel
sar
coronaviru
identifi
caus
agent
sever
pneumonialik
coronaviru
diseas
covid
outbreak
wuhan
hubei
provinc
china
envelop
positivesens
singlestrand
rna
betacoronaviru
relat
virus
caus
notabl
level
report
correl
respiratori
failur
inhibitor
current
pursu
clinic
studi
amelior
virusinduc
inflammatori
respons
patient
preexist
chronic
condit
hypertens
diabet
asthma
well
year
older
higher
risk
sever
diseas
outcom
underli
basi
differenti
outcom
yet
unknown
togeth
still
acceler
rate
commun
transmiss
sever
symptom
place
unpreced
burden
medic
suppli
chain
health
care
system
itali
spain
us
similar
scenario
play
anticip
countri
fda
recent
grant
antimalari
drug
hydroxychloroquin
sulfat
also
known
hydroxychloroquin
emerg
use
author
eua
treatment
present
vaccin
approv
antivir
therapeut
agent
avail
thu
urgent
critic
need
identifi
novel
medic
countermeasur
prophylact
treatment
use
sinc
product
vaccin
could
take
month
de
novo
develop
therapi
usual
requir
year
reposit
clinic
evalu
drug
repres
one
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
practic
strategi
rapid
identif
deploy
treatment
emerg
infecti
diseas
toward
end
addit
mani
antiimmun
treatment
address
paper
mani
investig
clinic
trial
use
repurpos
drug
evalu
direct
antivir
activ
alreadi
launch
includ
multipl
antivir
antimalari
medicin
earli
result
multicent
trial
china
suggest
antimalari
drug
chloroquin
may
limit
exacerb
pneumonia
shorten
viral
replic
cours
diseas
french
studi
use
hydroxychloroquin
togeth
azithromycin
report
signific
reduct
viral
load
patient
use
combin
howev
suffici
power
casecontrol
studi
yet
report
thu
unclear
therapeut
benefit
chloroquin
administr
patient
although
sever
concern
rais
recent
due
sever
cardiac
complic
potenti
result
use
treatment
patient
repurpos
sever
approv
antivir
therapi
focu
clinic
investig
includ
proteas
inhibitor
lopinavirritonavir
kaletra
aluvia
abbvi
hepat
c
viru
proteas
inhibitor
danoprevir
ganovo
ascleti
pharma
influenza
antivir
favipiravir
avigan
notabl
ten
clinic
trial
global
site
underway
investig
remdesivir
investig
antivir
origin
develop
gilead
scienc
treat
ebola
viru
infect
remdesivir
adenosin
analogu
viral
rna
polymeras
inhibitor
caus
prematur
termin
transcript
incorpor
nascent
viral
rna
drug
demonstr
vitro
vivo
activ
anim
model
mer
sar
well
potent
antivir
activ
vero
clinic
isol
pend
result
sever
random
n
clinic
trial
expect
provid
definit
insight
efficaci
remdesivir
therapeut
solut
treatment
howev
wellpow
random
control
trial
yet
demonstr
definit
evid
antivir
efficaci
remdesivir
potenti
therapeut
target
repurpos
strategi
provid
potenti
rapid
trajectori
toward
approv
treatment
unbias
largescal
evalu
known
drug
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
clinic
candid
identifi
addit
unanticip
therapeut
option
acceler
evalu
treatment
diseas
describ
highthroughput
reposit
screen
use
commerci
librari
pharmacolog
activ
compound
refram
repurpos
focus
rescu
acceler
medchem
drug
collect
comprehens
openaccess
librari
clinicalstag
approv
small
molecul
respect
identifi
exist
drug
harbor
antivir
activ
cellbas
assay
refram
librari
previous
use
success
identifi
antiinflammatori
auranofin
potenti
therapi
tuberculosi
approv
drug
clofazimin
potent
antiparasit
compound
test
efficaci
cryptosporidium
also
use
identifi
optim
fdaapprov
antifung
drug
itraconazol
novel
efficaci
molecul
suitabl
chronic
administr
antifibrot
importantli
refram
librari
uniqu
repurpos
collect
awar
nearli
librari
deriv
custom
synthesi
commerci
avail
sourc
clinic
molecul
avail
molecul
collect
previous
optim
efficaci
safeti
bioavail
therefor
enabl
leverag
consider
invest
research
develop
compress
timelin
requir
drug
discoveri
develop
exampl
reposit
estim
reduc
typic
year
develop
process
year
emerg
use
author
eua
chemic
biolog
radiolog
nuclear
cbrn
threat
public
health
emerg
pandem
may
abbrevi
time
frame
describ
highthroughput
analysi
refram
librari
identifi
inhibitor
replic
mammalian
cell
identifi
sever
target
mechanist
class
highli
enrich
includ
aldos
reductas
inhibitor
retino
acid
receptor
antagonist
benzodiazepin
receptor
agonist
regul
cholesterol
homeostasi
antimalari
compound
valid
studi
confirm
known
drug
inhibit
viral
replic
includ
four
molecul
previous
approv
fda
clofazimin
acitretin
tretinoin
astemizol
regist
outsid
us
tamibaroten
dose
respons
studi
thu
far
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
character
compound
exhibit
rang
effect
concentr
ec
consist
potenti
clinic
efficaci
includ
pikfyv
kinas
inhibitor
reach
phase
ii
clinic
trial
apilimod
cystein
proteas
inhibitor
z
lvg
ono
variou
phase
preclin
clinic
develop
addit
preclin
ion
channel
blocker
ion
channer
blocker
antimalari
drug
hanfangchin
phase
proton
pump
inhibitor
well
gprotein
receptor
antagonist
phase
ii
phase
clinic
evalu
respect
also
found
possess
antivir
activ
rapid
experiment
clinic
evalu
therapeut
vivo
antivir
efficaci
amelior
diseaseassoci
patholog
provid
import
opportun
acceler
develop
potenti
therapi
treatment
strain
isol
nasopharyng
aspir
specimen
laboratoryconfirm
patient
hong
kong
strain
isol
oropharyng
swab
patient
respiratori
ill
develop
clinic
diseas
januari
washington
usa
obtain
bei
resourc
viru
propag
vero
cell
transfect
exogen
human
store
aliquot
plaqu
form
unit
pfu
tcid
assay
perform
titrat
cultur
viru
vero
cell
apath
llc
brooklyn
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
heatinactiv
fetal
bovin
serum
fb
gibco
uml
penicillin
streptomycin
mm
sodium
pyruv
gibco
mm
hepe
gibco
mem
nonessenti
amino
acid
solut
gibco
cell
transfect
prior
infect
experi
involv
live
follow
approv
standard
oper
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
procedur
biosafeti
level
facil
univers
hong
kong
sanford
burnham
prebi
medic
discoveri
institut
librari
collect
pharmacolog
activ
compound
cover
major
target
class
includ
kinas
gpcr
neurotransmiss
gene
regul
sigma
refram
repurpos
focus
rescu
compound
refram
librari
transfer
fbottom
black
plate
greiner
use
echo
liquid
handler
labcyt
compound
dilut
cultur
media
final
concentr
screen
briefli
vero
cell
seed
plate
top
prespot
compound
densiti
cell
per
well
use
select
dispens
biotek
instrument
sixteen
hour
postseed
cell
infect
ad
per
well
moi
cytopath
effect
cpe
indirectli
quantifi
presenc
atp
live
cell
use
celltiterglo
promega
luminesc
cell
viabil
assay
hour
postinfect
data
normal
median
plate
refram
librari
zscore
calcul
base
averag
standard
deviat
plate
screen
perform
duplic
run
assay
parallel
librari
two
independ
experi
refram
collect
twentyeight
compound
select
accord
cutoff
stdev
includ
doserespons
confirm
assay
compound
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
refram
collect
rank
accord
zscore
top
hit
replic
select
overlap
seventyf
addit
hit
chosen
accord
rank
base
averag
zscore
last
hit
select
accord
drug
target
pathway
enrich
analysi
priorit
hit
includ
doserespons
confirm
assay
select
hit
valid
immunofluoresc
dose
respons
experi
determin
ec
block
bovin
serum
albumin
bsa
min
cell
incub
hour
room
temperatur
nucleoprotein
serum
exhibit
strong
crossreact
two
wash
phosphatebuff
salin
pb
cell
incub
alexa
fluor
goatantirabbit
igg
thermo
fisher
scientif
usa
hour
room
temperatur
two
addit
wash
pb
supplement
dapi
biolegend
usa
ad
cell
least
min
imag
imag
acquir
use
celigo
imag
cytomet
nexcelom
assay
result
data
analysi
enabl
us
determin
infect
viabilitycytotox
base
infect
cytotox
valu
logist
nonlinear
regress
model
use
calcul
ec
cc
concentr
valu
compound
annot
three
databas
use
assembl
refram
librari
clariv
integr
gvk
excelra
gostar
citelin
pharmaproject
accord
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
varieti
properti
includ
target
pathway
indic
mechan
action
moa
annot
properti
test
enrich
among
screen
hit
use
gsea
softwar
compound
annot
properti
treat
gene
set
set
vendor
annot
background
compound
set
defin
set
compound
annot
properti
vendor
enrich
result
p
fdr
qvalu
defin
signific
addit
enrich
analys
perform
use
free
onlin
metaanalysi
tool
metascap
gene
express
analysi
conduct
use
singlecel
rna
profil
data
sampl
four
macroanatom
locat
human
airway
epithelium
healthi
live
volunt
gener
r
use
pheatmap
viridi
packag
replic
one
effici
way
identifi
antivir
candid
emerg
viru
rapidli
evalu
clinic
trial
repurpos
clinic
assess
drug
given
urgent
need
therapeut
treat
infect
develop
highthroughput
assay
screen
comprehens
repurpos
librari
vero
cell
kidney
epitheli
cell
deriv
african
green
monkey
shown
highli
permiss
infect
viral
replic
assess
measur
viralinduc
cytopath
effect
cpe
clinic
isol
viru
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
util
assay
develop
screen
assay
paramet
includ
cell
seed
densiti
multipl
infect
moi
timepoint
optim
vero
cell
measur
virusinduc
cpe
use
celltiterglo
quantifi
cellular
atp
level
format
maxim
dynam
rang
reproduc
found
condit
cellswel
infect
moi
cpe
measur
hour
postinfect
figur
data
shown
effort
assess
robust
reproduc
optim
assay
highthroughput
screen
ht
configur
initi
evalu
assay
util
duplic
plate
run
parallel
valu
correspond
well
normal
median
plate
use
calcul
log
base
fold
chang
base
activ
averag
factor
plate
duplic
correl
coeffici
duplic
r
figur
although
usual
distribut
posit
control
correl
plot
observ
twentyeight
compound
select
studi
base
activ
screen
includ
hiv
proteas
inhibitor
nelfinavir
mesyl
hydrat
calpain
cathepsin
b
inhibitor
antagonist
serotonin
receptor
gr
hydrochlorid
hydrat
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
shown
effici
block
either
infect
vitro
vivo
thu
assess
sensit
screen
condit
identifi
compound
known
antivir
activ
figur
top
right
middl
panel
reposit
analysi
refram
drug
repurpos
librari
sinc
result
ht
analysi
indic
assay
condit
suitabl
progress
largescal
screen
use
experiment
design
screen
comprehens
refram
drug
repurpos
collect
librari
inclus
collect
nearli
chemic
compound
either
fdaapprov
regist
outsid
us
enter
clinic
trial
undergon
signific
preclin
character
specif
compound
array
plate
final
concentr
previou
assay
vero
cell
seed
well
prespot
compound
infect
h
later
moi
hour
postinfect
cpe
determin
analysi
averag
factor
calcul
activ
determin
reflect
accept
assay
dynam
rang
figur
left
panel
screen
repeat
independ
replic
correl
coeffici
r
two
replic
determin
figur
base
nomin
pvalu
cutoff
fdr
qvalu
found
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
enrich
target
biolog
process
includ
alloster
modul
benzodiazepin
retino
receptor
cytosol
nadphdepend
oxidoreductas
aldos
reductas
potassium
channel
cholesterol
homeostasi
serin
proteas
antimalari
includ
chloroquin
deriv
ie
amopyroquin
also
enrich
although
fdr
qvalu
establish
threshold
figur
figur
tabl
primarili
infect
epitheli
cell
respiratori
tract
elucid
express
pattern
gene
annot
target
put
antivir
compound
compar
express
drug
target
gene
enrich
compound
screen
across
cell
type
within
respiratori
tract
although
entri
receptor
prime
proteas
found
express
within
specif
anatom
sampl
locat
respiratori
tract
figur
left
heatmap
express
found
restrict
epitheli
cell
type
includ
multicili
nasal
deuterosom
secretori
basal
cell
figur
right
heatmap
nonetheless
express
report
induc
typei
interferon
notabl
major
map
target
activ
compound
also
harbor
express
relev
respiratori
epitheli
cell
suggest
may
physiolog
relev
drug
target
figur
pathway
analys
enrich
moa
target
reveal
enrich
gene
involv
nuclear
receptor
pathway
gpcr
ligand
bind
signal
calcium
signal
figur
underscor
potenti
critic
role
molecular
circuit
cellular
control
life
cycl
candid
valid
studi
compound
rank
accord
zscore
primari
screen
figur
compound
replic
priorit
base
rank
addit
molecul
select
found
replic
compound
also
select
accord
rank
calcul
base
averag
zscore
replic
addit
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
hit
chosen
classifi
within
enrich
drug
target
pathway
class
see
initi
assess
activ
hit
half
origin
screen
concentr
use
orthogon
assay
readout
specif
vero
cell
preincub
compound
dilut
although
specif
compound
therapeut
dose
rang
typic
expect
track
cellular
ec
well
concentr
therefor
conduct
dose
respons
analysi
determin
relationship
compound
concentr
antivir
activ
compound
concentr
test
rang
nm
immunofluoresc
assay
describ
previous
total
cell
count
use
assess
compound
cytotox
figur
addit
remdesivir
treatment
compound
result
discern
dosedepend
antivir
activ
could
segreg
base
broad
function
structur
targetbas
class
figur
known
drug
ec
nm
valu
could
exactli
extrapol
figur
figur
compound
harbor
ec
nm
reach
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
inhibiton
infect
highest
concentr
figur
suggest
effect
antivir
potenc
could
like
achiev
therapeut
dose
patient
data
also
avail
reframedborg
enabl
priorit
known
drug
preclin
clinic
evalu
treatment
summari
publicli
disclos
relev
preclin
clinic
properti
advanc
among
molecul
annot
tabl
inform
retriev
cortellistm
clariv
analyt
drugscom
sinc
begin
januari
extraordinari
number
investig
program
clinic
trial
initi
concert
effort
identifi
therapeut
rapidli
grow
pandem
clinic
trial
use
repurpos
clinicalstag
approv
drug
remdesivir
favipiravir
lopinavirritonavir
hydroxychloroquin
other
investig
treat
patient
therapi
treatment
antibodi
seroconvert
idividu
also
investig
howev
report
studi
conduct
small
cohort
thu
consid
preliminari
larger
casecontrol
clinic
evalu
still
pend
elucid
addit
candid
therapi
would
greatli
enhanc
probabl
rapidli
identifi
safe
efficaci
treatment
option
would
also
enabl
develop
combinatori
regimen
cocktail
reflect
current
treatment
strategi
hepat
c
viru
hcv
largescal
survey
exist
drug
may
harbor
antivir
activ
significantli
facilit
reposit
effort
recent
report
proteinprotein
interact
ppi
analysi
identifi
viralhost
interact
potenti
druggabl
human
host
factor
target
known
drug
fda
approv
howev
activ
replic
yet
report
addit
studi
test
focus
panel
fdaapprov
drug
previous
shown
antivir
activ
sarscov
merscov
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
also
demonstr
sever
known
drug
harbor
potent
antivir
activ
report
highthroughput
analysi
approxim
known
drug
evalu
activ
replic
assay
conduct
vero
cell
design
captur
multicycl
replic
base
upon
low
viral
input
moi
extend
endpoint
measur
hour
postinfect
although
cellbas
assay
bias
toward
captur
inhibitor
viral
entri
assay
construct
interrog
step
viral
life
cycl
note
one
potenti
limit
vero
cell
due
speci
differ
prodrug
requir
human
host
cell
machineri
process
activ
form
nucleosid
inhibitor
may
harbor
potenc
human
cell
consist
found
remdesivir
inhibit
replic
potent
human
cell
comparison
vero
cell
figur
figur
data
shown
dynam
rang
viralinduc
cpe
assay
small
fold
robust
reproduc
figur
optim
use
first
refram
collect
screen
display
accept
factor
respect
duplic
refram
screen
reduc
dynam
rang
correspond
factor
although
correl
two
refram
replic
high
r
compound
found
activ
replic
replic
figur
bottom
right
middl
panel
leverag
dataset
select
molecul
valid
compound
select
weight
replic
specif
addit
molecul
librari
drug
select
base
activ
addit
one
belong
enrich
targetmoa
set
base
gsea
analysi
also
includ
select
compound
test
orthogon
assay
directli
measur
viral
replic
contrast
indirect
measur
replic
assess
cpe
took
advantag
highthroughput
immunofluoresc
assay
monitor
infect
level
reflect
n
protein
express
singl
cell
resolut
importantli
valid
step
enabl
separ
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
molecul
function
block
cpe
ie
cell
death
instead
direct
effect
replic
assay
found
robust
timepoint
use
moi
thu
antivir
activ
compound
interrog
origin
moi
timepoint
condit
earlier
timepoint
higher
moi
like
bias
valid
screen
toward
confirm
earli
stage
inhibitor
consist
hypothesi
found
sever
molecul
potent
ec
abl
inhibit
replic
approxim
multipl
high
concentr
includ
figur
figur
may
repres
maxim
abil
molecul
suppress
viral
replic
altern
analysi
molecul
util
lower
moi
later
timepoint
may
reveal
greater
inhibit
infect
addit
valid
assay
conduct
employ
drug
concentr
half
util
screen
versu
use
second
isol
introduct
stringenc
valid
step
well
fals
posit
activ
ht
assay
like
account
confirm
rate
observ
step
analysi
tretinoin
clofazimin
acitretin
amongst
notabl
valid
compound
sinc
approv
fda
clofazimin
lipophil
riminophenazin
antibiot
describ
antimycobacteri
antiinflammatori
activ
use
treatment
leprosi
main
advers
effect
includ
chang
skin
pigment
nausea
vomit
antibacteri
activ
clofazimin
describ
relat
abil
bind
bacteri
dna
interestingli
compound
also
identifi
potent
antiparasit
drug
activ
cryptosporidium
repurpos
screen
refram
librari
studi
requir
understand
mechan
molecul
block
replic
positivestrand
rna
viru
determin
doserespons
relationship
clofazimin
enabl
assess
whether
antivir
efficaci
achiev
therapeut
dose
acitretin
approv
oral
bioavail
retinoid
use
treatment
psoriasi
tretinoin
togeth
tamibaroten
regist
japan
well
tamibaroten
tazaroten
rbad
valid
compound
belong
enrich
gsea
class
class
retino
acid
agonist
highli
enrich
gsea
analysi
figur
current
unclear
activ
transcript
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
program
govern
retino
acid
receptor
may
imping
upon
replic
six
addit
compound
confirm
valid
studi
also
modul
target
enrich
highthroughput
screen
includ
aldos
reductas
inhibitor
al
benzodiazepin
receptor
agonist
zaleplon
gr
pagoclon
two
antimalari
drug
hanfangchin
antimalari
drug
report
effect
block
sever
viral
infect
includ
howev
activ
mani
particular
chloroquin
deriv
recapitul
clinic
trial
drug
belong
class
gener
report
less
effect
block
viral
infect
compar
antimalari
activ
ec
gener
rang
concentr
requir
antivir
activ
could
thu
like
difficult
reach
human
without
caus
advers
effect
taken
togeth
confirm
compound
membership
enrich
target
class
underscor
import
molecular
circuit
regul
replic
support
evalu
addit
preclin
clinic
stage
molecul
target
overrepres
mechan
among
compound
valid
show
doserespons
relationship
orthogon
assay
compound
harbor
ec
antivir
activ
nm
suggest
addit
preclin
studi
like
requir
determin
whether
administr
compound
achiev
suffici
system
exposur
enabl
antivir
activ
figur
seven
molecul
found
inhibit
viral
replic
ec
concentr
nm
includ
z
lvg
preclin
tripeptid
deriv
display
broadspectrum
bactericid
activ
specif
molecul
previous
shown
suppress
herp
simplex
viru
hsv
replic
inhibit
enzymat
activ
hsvencod
cystein
proteas
may
indic
antivir
function
z
lvg
occur
inhibit
proteas
anoth
preclin
molecul
exhibit
strong
antivir
activ
mdl
potent
cell
permeabl
calpain
ii
inhibitor
interestingli
mdl
previous
found
impair
infect
ebola
viru
ebov
addit
astemizol
regist
antihistamin
receptor
antagonist
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
also
report
antimalari
properti
inhibit
replic
ec
concentr
due
fatal
arrhythmia
given
high
dose
combin
certain
common
drug
astemizol
withdrawn
mani
countri
therefor
thorough
safeti
studi
requir
determin
exist
suffici
therapeut
index
acut
treatment
infect
oral
activ
chemokin
antagonist
evalu
phase
ii
clinic
studi
treatment
rheumatoid
arthriti
ra
multipl
sclerosi
ms
show
dose
mg
daili
well
toler
determin
inhibit
replic
estim
ec
concentr
nm
figur
c
max
compound
report
nm
mg
qd
therefor
addit
vivo
studi
requir
determin
suffici
system
concentr
reach
promot
antivir
activ
mechan
antagon
inhibit
infect
requir
investig
howev
report
inhibit
potenti
block
erk
phosphoryl
lead
suppress
mitogenactiv
protein
kinas
rafmekerk
signal
transduct
pathway
interestingli
rafmekerk
signal
pathway
employ
support
replic
via
multipl
welldocu
mechan
thu
signal
axi
may
also
repres
critic
therapeut
target
hostdirect
antivir
human
cysteinyl
cathepsin
includ
cathepsin
b
cathepsin
l
cathepsin
k
requir
proteolyt
process
viral
encod
protein
infect
cathepsin
activ
seem
requir
proper
process
protein
within
endosom
order
activ
fusogen
acit
inhibit
cathepsin
l
activ
previous
shown
effici
suppress
infect
found
ono
cathepsin
k
inhibitor
revers
cathepsin
proteas
inhibitor
inhibit
infect
dosedepend
manner
howev
addit
studi
requir
determin
antivir
activ
due
inhibit
proteolysi
viral
host
cellular
protein
ono
harbor
antivir
nm
rang
previous
report
activ
observ
nm
osteoclastmedi
bone
resorpt
assay
importantli
cmax
compound
mg
qd
treatment
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
well
toler
daili
dose
mg
month
without
clinic
relev
safeti
concern
reach
phase
ii
clinic
trial
treatment
osteoporosi
postmenopaus
women
develop
discontinu
due
unfavor
competit
landscap
preclin
develop
anoth
cathepsin
inhibitor
harbor
potenti
antivir
activ
nm
show
high
potenc
cathepsin
b
l
v
vitro
overal
identif
ono
effect
antivir
molecul
support
reposit
potenti
addit
proteas
inhibitor
treatment
diseas
final
apilimod
specif
pikfyv
kinas
inhibitor
found
inhibit
replic
ec
concentr
nm
figur
importantli
apilimod
found
well
toler
human
show
desir
safeti
profil
dose
mg
bid
cmax
compound
mg
qd
data
indic
therapeut
dose
apilimod
patient
achiev
concentr
like
promot
antivir
activ
apilimod
evalu
phase
ii
clinic
trial
treatment
activ
crohn
diseas
rheumatoid
arthriti
ra
addit
phase
ii
trial
oral
treatment
common
variabl
immunodefici
cvid
show
efficaci
indic
orphan
drug
design
grant
apilimod
us
treatment
follicular
lymphoma
phase
clinic
trial
ongo
notabl
report
apilimod
effici
inhibit
ebov
lassa
viru
lasv
marburg
viru
marv
human
cell
line
underscor
potenti
broadspectrum
antivir
activ
underli
mechan
inhibit
infect
apilimod
current
known
howev
sinc
pikfyv
predomin
resid
earli
endosom
play
essenti
role
mainten
endomembran
homeostasi
apilimod
like
block
viral
low
phdepend
entri
inhibit
lipid
kinas
activ
pikfyv
taken
togeth
studi
illumin
compendium
druggabl
target
pathway
biolog
process
small
molecul
modul
replic
cycl
data
leverag
focu
studi
aim
deciph
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
biolog
coronaviru
guid
addit
direct
repurpos
studi
particularli
exist
latestag
preclin
asset
critic
campaign
led
identif
valid
molecul
antivir
activ
includ
four
fdaapprov
compound
one
drug
regist
japan
molecul
enter
clinic
trial
avail
human
safeti
pharmacolog
data
molecul
expect
enabl
rapid
preclin
clinic
assess
compound
howev
expedit
regulatori
review
eua
guidelin
also
provid
rational
develop
earlier
stage
candid
molecul
deploy
use
current
pandem
outbreak
critic
multipl
therapeut
option
demonstr
efficaci
avail
mitig
potenti
emerg
drug
resist
well
enabl
evalu
optim
therapeut
cocktail
broadli
cur
diseas
follow
reagent
deposit
center
diseas
control
prevent
activ
clinic
profil
compound
confirm
doseact
relationship
enter
clinic
evalu
drug
target
enrich
gsea
analysi
ht
data
fdaapprov
gseaenrich
compound
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
